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 In Ethiopia, Co-trimoxazole prophylaxis therapy (CPT) used to prevent 
opportunistic infections among people living with HIV is the standard of 
practice; however incidence of opportunistic infection and their predictors 
are rarely documented in the country.  This was a retrospective follow up 
study to describe the incidence and predictors of opportunistic infections 
among 244 adults receiving CPT. Participants were followed for a median 
time of 72 weeks. During a study period a total of 53opportunistic infections 
were recorded; making the overall incidence rate 23.9/100 person-years. 
High incidence of opportunistic infections is likely to occur if: the clients 
were married (adjusted hazard ratio (AHR) 1.965;(95% CI: 1.109, 3.451), 
had history of tuberculosis treatment (AHR: 2.34(95% CI:1.05, 5.24)), 
patients who are indicated for CPT because of both clinical and WHO 
clinical staging criteria(AHR 2.418 (95% CI:1.02, 5.72 ),and had poor 
adherence to CPT (AHR, 2.11 (95% CI: 1.19-3.72)). Eventhough adherence 
is non-substitutable strategy to prevent opportunistic infection, the cohort of 
HIV patients failed to adhere to CPT, which in turn resulthigh incidence of 
opportunistic infections among them, therefore improving adherence as 
guideline should be a priority to prevent OIs among people living with HIV 
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1. INTRODUCTION  
Human Immune Virus (HIV) is one of the world health and development challenges, and more than 
34 million people are living with HIV and around million new infections occurred in the year 2011 [1],[2]. 
Regarding prevention and control of HIV/AIDS Ethiopia is showing remarkable results with 1.5 % of adult 
HIV prevalence [3]. However, opportunistic infections (OIs) continue to be a major cause of morbidity and 
mortality for people living with HIV in the country [4],[5]. Prophylaxis against common OIs is a 
recommended strategy to improve the quality of life of people infected with HIV through preventing early 
morbidity and mortality [4],[6].  
Co-trimoxazole (a combination of sulfamethoxazole and trimethoprim) is a broad spectrum safe, 
well tolerated, low-cost, and widely available antimicrobial agent used as standard care for people living with 
HIV and also used in primary health care to treat various infections [6]-[10]. The Ethiopian national 
guideline recommends CPT for people living with HIV if one of the following conditions is fulfilled: 1. 
WHO clinical stage 2, 3 or 4 in the absence of CD4 count, 2. WHO clinical stage 3 or 4 irrespective of CD4 
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level, 3. CD4 count < 350 cell/mm3, 4. TB-HIV co-infected patient or 5. patient with a documented prior 
history of Pneumocystis Carini Pneumonia (PCP) [6],[7]. 
Studies confirmed that CPT significantly reduces morbidity and mortality in HIV positive people 
even in the area where the drug is highly resisted or malaria is endemic [9]-[17]. Nevertheless, the global 
implementation of CPT has been rated as sub-optimal [14],[18]. In Ethiopia CPT is taking place in 2006 but 
little has been known about the incidence of common OIs such as bacterial pneumonia, diarrhea disease, 
septicemia, enteritis, malaria or PCP among HIV positive people on CPT [4]. This study aimed to describe 
the incidence of common OIs among HIV positive people on CPT at Arba Minch Hospital since 2003 which 
provides care to cohorts of people with HIV. 
 
 
2. RESEARCH METHOD  
 
2.1. Study setting  
This study was conducted at Arba Minch Hospital (AMH) which is located at Arba Minch town, 
Gamo Gofa Zone, South Ethiopia which is 500 km in south of Addis Ababa. The hospital provides 
comprehensive HIV care to all HIV positive people within Gamo Gofa zone or out. It is also one of few 
Ethiopian hospitals who started CPT to patients at the first time. The services are provided by 
multidisciplinary team which includes physicians, nurses, public health professionals, laboratory 
technologists, pharmacists, data clerks and volunteer who are adherence supporters. In case of illness, the 
hospital treats patients according to the national guideline for HIV management.    
 
2.2. Patient selection 
All adult patients who were registered from Sep 1, 2008 up to Aug 30, 2011 in chronic HIV care 
clinic plus who had both medical record chart and ART follow up chart were included in the study. This 
period was selected in order to have the recent possible 72 week (this period is considered the time period in 
which CPT is effective) follow up time [19]. Out of 768 patients registered within the given period, 244 
patients become eligible and followed for maximum of 72 weeks (1.38 person years) based on the time when 





Figure 1. Participant inclusion flowchart, Arba Minch Hospital, Ethiopia 
 
 
2.3. Study design and data collection 
A retrospective follow up study was used. A structured and pretested data collection checklist was 
prepared and used to collect demographic, baseline clinical and hematological characteristics and follow up 
condition of the patients. Two health professionals who had bachelor degree with a special training for HIV 
care were selected to review records. 
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2.4. Statistical analysis  
Data were entered in to Epinfo 7.1.0 and analyzed using the Statistical Package for the Social 
Science (SPSS) software package, version 20. The main outcome variables are morbidity (malaria, diarrhea, 
pneumonia, PCP and enteritis) and time to occurrence of morbidity within 72 weeks.  
Survival time was calculated in weeks between the date of CPT initiation and (1) the date of event 
(morbidity), (2) the date transferred out (TO), (3) the date of the first missed appointment for lost cases, and 
(4) the date on which the patient completed the 72 weeks of follow up. The Kaplan Meier and Log rank test 
used to estimate survival probability and compare survival curves respectively. The Cox proportional hazard 
model was used to assess the relationship between baseline variables and morbidity after checking 
proportional hazard assumption using global goodness-of-fit test (Schoenfeld's method).  
 
2.5. Ethical approval  
Institutional ethical approval was obtained from the research and publication committee ethical 
review board of university of Gondar, Institute of Public Health. We obtained written permission from Gamo 
Gofa zone administration and AMH. 
 
 
3. RESULTS AND ANALYSIS  
 
3.1. Participant profile  
Between September, 2008 and August 2011, 1209 patients were enrolled in chronic ART clinic, of 
them 768 patients were on CPT but only 244 patients who have both medical record and ART follow up 
chart were included in the study (Figure 1).  
 
3.2. Description of study subject and incidence of OIs 
Out of 244 patients 159 (57%) were female with mean age of 34.1years (SD: 10.1) and most of them 
were unemployed and urban dweller as shown in Table 1.  
 
 
Table 1. Demographic characteristic of participants at Arba Minch Hospital 
Character Number Percent 
Sex 
Male 105 43 
Female 139 57 
Occupation 
Employed 52 21.3 
Self-employed 61 25 
Unemployed 131 53.7 
Education level 
No formal education 54 22.1 
Primary 90 36.9 
Secondary 76 31.1 
Tertiary 24 9.8 
Residence 
Urban 207 84.8 
Rural 37 15.2 
Family size 
1 -3 114 46.7 
>3 130 53.3 
Age group 
< or = 23 27 11.1 
24 – 33 105 43 
34 – 43 76 31.1 
>or = 44 36 14.8 
Marital status 
Married 142 58.2 
Other 102 41.8 
 
 
Participants contributed for 221.327 person-years (PY) of follow up and average period of follow-up 
was 47.17 (SD± 28.7) weeks. The median CD4 count was 157 (IQR: 79 - 241) cells/ mm3.  Of the 244 
participants 161 (66%) had CD4 < 200 cells/mm3, 226 (92.6%) were on ART and 63 (25.8%) had poor 
adherence to drugs, of which 22(34.9%) developed OI. 
During the follow up period, 53 cases were recorded as having OIs, 11 were lost to follow up, 5 
transferred out, 14 stopped treatment, 34 died and 127 did not develop event during follow up. Fifty three 
cases make the overall incidence rate 23.9/100 PY (95% CI; 18.3, 29.5) of them 37% were malaria, 24.5% 
were pneumonia, 16.9% were enteritis, 13.2% were diarrhea and 3.8% were PCP. Two or more disease 
episodes were reported in 2 (3.8%) clients and only 3 (5.7%) patients were admitted to hospital. 
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3.3. Association of OIs with baseline and follow up characteristics  
Overall cumulative probability of survival beyond 72 weeks was 0.74 and the median survival time 
was 59.7 (95% CI: 56.2, 62.5).Compare patients with TB treatment history, adherence to CPT, criteria to 
initiate CPT and marital status, had significant association with survival time (Figure 2-5 below respectively). 
Baseline CD4 count [CHR 0.831 (95% CI: 0.47, 1.48)] and WHO clinical stages [CHR 1.49 (95% CI: 0.85, 









Figure 3. Kaplan–Meier curve of probability of remaining free from OIs over time, by level of adherence to 
Co-trimoxazole prophylaxis 
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Figure 5. Kaplan–Meier curve of probability of remaining free from OIs over time, by marital status 
 
 
Multiple variable cox regression analysis revile that adherence to CPT was an important predictor of 
risk for opportunistic infection, CHR was 2.087 (95% CI: 1.208, 3.604) for patients with poor adherence to 
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Table 2. Predictors of opportunistic infections among HIV positive patient 
 
 
4. DISCUSSION  
Here we describe incidence of OIs by demographic, baseline clinical condition and follow up result 
of 244 HIV patients receiving Co-trimoxazole prophylaxis and followed up for median 59.7 weeks in Arba 
Minch hospital. In these patients diagnosis and treatment heeled according to the national standard of 
treatment but some diagnosis were conducted syndromeically may exaggerate incidence rate.    
This study indicated that, the overall incidence rate of OIs in patients on CPT was 23.9/100 PY 
(95% CI; 18.3, 29.5), which usually occurred within the first 22 weeks primarily due to malaria and 
pneumonia, it is higher compared to observational study from South Africa has reported incidence rate 
0.48/100 person month [20] but lower than finding from Coˆ te d’Ivoire  [21]. Low incidence rate observed in 
present study might be due to considering only major Co-trimoxazole preventable infections. In our study 
malaria was major type of OIs which is greater than findings from Coˆ te d’Ivoire (3.9/100 PY) and Uganda 
(3.7/100PY) [21],[22], this greater rate of malaria probably because of two things, the first one is the place is 
very endemic area for malaria and the second reason is by the time of follow up any febrile case was treated 
as malaria using syndromic approach. But the finding is consistent with finding from Malawi [23]. The rate 
of pneumonia is higher compared to the result from Coˆ te d’Ivoire 2.7/100 PY [21] but lower compared with 
finding from Malawi [23].Incidence rate of diarrhea was higher in Uganda and Malawi 10.2/100 PY and 
37/100 PY respectively [22],[23]. 
In this study, patients having poor adherence had a significantly high risk of developing OIs than 
patients having good adherence (AHR was 2.108 95% CI1.194-3.72); this high rate of infection in poorly 
adhere patients is might be inconsistence or inappropriate use of drug reduce the efficacy. In this study, 
marital status of patients significantly affect incidence of OIs; unmarred patients are nearly two times at risk 
of developing Co-trimoxazole preventable OIs; less support for adherence for unmarried patients might 
increase risk of developing OIs. Patients initiated CPT if they meet both WHO clinical staging and CD4 
count more like develop OIs than patients initiated by ether of the criteria;  this might be patients started if 
they meet both criteria were in advanced stage of disease status. 
In this study patients categorized in to two baseline CD4 count (CD4 count < 200 cell/mm3 and CD4 
≥ 200 cell/mm3) were equal likely affected by morbidity; this finding is consistent with findings from other 
studies [10],[14],[17],[24],[25]. This finding reveal that patients by baseline WHO clinical stage (WHO stage 
Characteristics Number PY Event CHR (95% CI) AHR (95% CI) 
Education      
No formal education 54 44.44 16 1 1 
Primary 90 87.21 19 0.64 (.33-1.24) 0.647 (0.329, 1.271) 
Secondary 76 67.54 16 0.67 (.33-1.34) 0.677 (0.335, 1.368) 
Tertiary 24 22.13 2 0.26 (.06-1.13) 0.252 (0.057, 1.113) 
Marital status      
Married 142 131.88 25 1 1 
Not married 102 89.44 28 1.63 (.95-2.79) 1.965 (1.109, 3.451) 
Residence      
Urban 207 186.23 41 1 1 
Rural 37 35.10 12 2.09 (1.21-3.60) 1.244 (0.635, 2.436) 
Family size      
1-3 114 106.88 21 1 1 
4-12 130 114.44 32 1.42  (0.81-2.45) 1.74 (0.96, 3.16) 
Weight 244 221.33 53 0 .99 (.95-1.00) 0.992 (0.963, 1.020) 
WHO stage      
I & II 104 102.13 19 1 1 
III & IV 140 119.19 34 1.49 (0.85, 2.62) 1.35 (0.69, 2.66) 
CD4 count      
< 200 161 139.33 36 1 1 
≥ 200 83 82 17 .831 (.47, 1.48) 0.678 (.36, 1.26) 
TB treatment      
Yes 55 53.08 7 1 1 
NO 189 168.25 46 2.04 (0.92, 4.53) 2.34(1.05, 5.24) 
Functional status      
Working 159 149.67 40 1 1 
Ambulatory & bedridden 85 71.65 13 0.66 (0.35, 1.24) 0.645 (0.337, 1.236) 
Criteria to indication CPT      
CD4 count/ WHO stage 51 55.5 6 1 1 
Both 193 165.83 47 2.6 (1.07, 5.84) 2.418 (1.02, 5.72) 
Adherence      
Good 181 165.63 31 1 1 
Poor 63 55.69 22 2.09 (1.21-3.60) 2.108 (1.19-3.72) 
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1 or 2 and WHO stage 3 or 4) equally at risk of developing OIs; this finding is consistent with results from 
other studies [9],[17],[24]. 
 
Limitation of the study 
Because of the retrospective nature of the data collection, we relied on the available information for 
the number and types of diseases reported during follow up. Some of the diagnoses were presumptive as 




Incidence rate of OIs among HIV positive people treated at Arba Minch Hospital ART clinic was 
high. More importantly, patient poor adherence to CPT was associated with high risk of incidence rate of 
OIs. The need to strengthen the strategies to enhance adherence to CPT is strongly recommended. Future 
research should be done using prospectively design to identify another cause for high incidence rate of OIs 
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